Other News to Note
Amarantus Bioscience Holdings Inc., of San Francisco, completed the in-licensure of Eltoprazine from PGI Drug Discovery LLC, giving it worldwide rights except for Asian territories. The company plans to start a Phase IIb trial this year to treat Levadopa-induced dyskinesia associated with Parkinson’s disease. Eltoprazine is a 5HT1a/1b partial agonist small-molecule drug candidate.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST